Skip to main content

Why Alibaba’s Hong Kong IPO May Signal a Chinese Retreat From Wall Street

This article first appeared in Data Sheet, Fortune's daily newsletter on the top tech news. To get it delivered daily to your in-box, sign up here.

Clay Chandler here, filling in for Adam from rainy Hong Kong where everybody is buzzing about Alibaba.

As we briefly mentioned on Tuesday, the Chinese tech behemoth is mulling a secondary listing on the Hong Kong exchange to raise $20 billion later this year. The company isn’t commenting.

But in this city, where finance floats nearly everyone’s boat in one way or another, a deal that rich would be cause for jubilation--and a huge coup for Hong Kong Exchanges & Clearing (HKEC), which operates this city’s bourse. In 2014, when Alibaba first sought to go public, Jack Ma and other founders snubbed Hong Kong because HKEC refused to allow dual-class shares granting different voting rights for different stocks. Alibaba listed instead on the New York Stock Exchange, where it raised a record $25 billion. (HKEC has since dropped the dual-class ban.)

And yet Alibaba’s return to Hong Kong also reflects the tempestuous state of U.S.-China relations. As we noted in Data Sheet last week, the escalating trade war between the two nations is morphing into a tech war. Word of Alibaba’s Hong Kong IPO--which comes days after a move by the Trump administration to forbid American firms from selling technology to Huawei Technology--has inspired a new fear: that tensions are spreading to capital markets, too.

The Financial Times warns that Alibaba, after setting the record for world’s richest IPO, “is about to set a new standard for a politically motivated one.” Bloomberg analysts Tim Culpan and Nisha Gopalan argue “politics may be the most obvious consideration” influencing Alibaba’s decision to list in Hong Kong. “By coming closer to home, Alibaba shows Beijing where its loyalties lie; and authorities can revel in what they see as an example of China’s growing power.” (They also speculate, though, that Alibaba will be able to put the money to good use.)

Meanwhile, the New York Times reports that trade hawks are urging Trump to “curb China’s access to Wall Street” to force Beijing back to the negotiating table.

Alibaba’s New York debut was hailed by many as a milestone in the integration of the U.S. and Chinese economies. In the years that followed, scores of Chinese companies emulated Alibaba’s example, bypassing Hong Kong to raise hundreds of billions of dollars on American exchanges. If Alibaba does float shares in Hong Kong later this year, its IPO could mark the beginning of a Chinese retreat from The Street.



from Fortune http://bit.ly/2JMuEMw
Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more